Wedbush Maintains Outperform on Immunome, Raises Price Target to $35
Immunome, Inc.
Immunome, Inc. IMNM | 0.00 |
Wedbush analyst David Nierengarten maintains Immunome (NASDAQ:
IMNM) with a Outperform and raises the price target from $31 to $35.
Wedbush Maintains Outperform on Immunome, Raises Price Target to $35
Immunome, Inc. IMNM | 0.00 |